Second Sight Medical Products (NASDAQ:EYES) released its quarterly earnings results on Wednesday. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.04), Morningstar.com reports. The business had revenue of $1.13 million for the quarter, compared to analysts’ expectations of $1.70 million. Second Sight Medical Products had a negative net margin of 508.90% and a negative return on equity of 809.08%.
Second Sight Medical Products stock traded down $0.03 during mid-day trading on Thursday, reaching $0.93. 1,945 shares of the company’s stock traded hands, compared to its average volume of 337,900. The company has a market cap of $117.90 million, a price-to-earnings ratio of -1.81 and a beta of 2.30. Second Sight Medical Products has a 12-month low of $0.63 and a 12-month high of $2.25.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Second Sight Medical Products from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine downgraded shares of Second Sight Medical Products from a “hold” rating to a “sell” rating in a research note on Tuesday.
TRADEMARK VIOLATION WARNING: “Second Sight Medical Products (EYES) Announces Earnings Results, Misses Expectations By $0.04 EPS” was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.themarketsdaily.com/2019/05/16/second-sight-medical-products-eyes-announces-earnings-results-misses-expectations-by-0-04-eps.html.
About Second Sight Medical Products
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. It focuses on developing new technologies to treat the population of sight-impaired individuals. The company is developing the Orion Visual Cortical Prosthesis, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma.
Featured Story: How Does the Quiet Period Work?
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.